Axogen, Inc. (AXGN) AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
AxoGen, Inc. NASDAQ:AXGN Healthcare · Medical - Devices
Pre Pre-market $50.50 Close $50.02 AH $50.00 Now $50.50 PM VOL 200 $ Vol ≈ $10K RVOL 1.01x
Close $50.02 +2.61% AH $50.00 +1.00% since
Mkt Cap $2.99B
PM VOL 200 sh
$ Vol ≈$10K
RVOL 1.01×
Press Release
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen management will participate in three upcoming investor conferences: Canaccord Genuity's MedTech Forum on November 11, Jefferies Global Healthcare Conference in London on November 17, and Piper Sandler's Healthcare Conference on December 2.
Participation includes fireside chats and/or presentations plus 1x1 investor meetings, with webcasts available on the company's investor relations site and replays archived for 90 days.
The release contains no new financial, clinical, or business updates — it is a scheduling notice.
• 5d ago AI analysis › Press Release ● Major ⚠ 3
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Axogen reported Q3 2026 revenue of $75.8 million, up 26.2% year-over-year, with net income of $2.3 million ($0.04 per share) and adjusted EPS of $0.21.
Adjusted EBITDA rose to $13.4 million from $9.2 million, gross margin was 74.8%, and cash plus investments reached $350.1 million after an upsized $225 million net offering, of which $200 million funded the BioCircuit acquisition completed October 1.
Commercial payer coverage for Avance now spans roughly 96% of U.S. covered lives following positive decisions from Elevance and Aetna, and the company will begin prostate market development in 2027.
Management reaffirmed 2026 guidance of at least $290 million in revenue (at least 29% growth, including $7 million from BioCircuit) with at least 73% gross margin and positive full-year free cash flow.
• 12d ago AI analysis › Press Release
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Axogen will release its third quarter 2026 financial results on Wednesday, October 28, 2026.
Management will host a conference call and webcast at 8:00 a.m. ET the same morning, with a replay and slides available on the investor relations site.
This is a scheduling notice only and contains no financial results or guidance.
• 26d ago AI analysis › Press Release ⚠ 4
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
This GlobeNewswire item is a paid promotional commentary by Wall Street Investor whose featured subject is Conexeu Sciences (CNXU), not the filer Axogen.
Axogen appears only as sector context: Q2 2026 revenue of $69.7 million, up 23.1%, with Breast segment growth above 50% and FY2026 guidance raised to at least $279 million.
The disclaimer confirms the publisher was compensated to promote Conexeu and that Axogen and other named companies are 'not peers, competitors, or financial comparables' and not involved in the article.
• 1mo ago AI analysis › Press Release
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
prnewswire.com • 1mo ago Press Release ● Major
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Axogen completed its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless device for peripheral nerve repair.
BioCircuit is expected to contribute roughly $6 million to Q4 2026 revenue and approximately $34 million in 2027, contributions not included in Axogen's existing guidance of at least 24% revenue growth for 2026.
Axogen reaffirmed full-year expectations of at least 73% gross margin and free-cash-positive results, and plans to commercialize NerveTape through its direct sales and hospital contracting infrastructure.
• 1mo ago AI analysis › Press Release ● Major ⚠ 2
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Axogen priced an underwritten public offering of 4.91 million common shares at $42.50 per share, for expected gross proceeds of roughly $208.7 million.
Underwriters hold a 30-day option on up to 736,500 additional shares; BofA Securities, Jefferies and Wells Fargo are lead book-runners, with Mizuho as bookrunner and Lake Street as co-manager, and the deal is expected to close September 11, 2026.
Substantially all net proceeds will fund the cash consideration for the previously announced acquisition of BioCircuit Technologies, with any remainder going to general corporate purposes.
Notably, the offering is not conditioned on the BioCircuit deal closing — if the acquisition falls through, the proceeds shift to general corporate purposes, leaving shareholders with the dilution but none of the strategic benefit.
• 1mo ago AI analysis › Press Release ● Critical ⚠ 4
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Axogen has signed a definitive agreement to acquire BioCircuit Technologies for $200 million in cash, adding NerveTape, the first FDA-cleared device for sutureless repair of transected peripheral nerves.
The transaction is expected to close in the fourth quarter of 2026 and will be funded with net proceeds from a public offering of Axogen common stock announced the same day.
Axogen expects the deal to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year following close while remaining free cash flow positive, with Axogen's direct sales force and hospital contracting expected to accelerate NerveTape adoption.
Updated full-year 2026 guidance including BioCircuit will come after closing; assuming a 2026 close, management anticipates the acquisition to be additive to 2027 revenue and accretive to gross margin and adjusted EBITDA margin.
• 1mo ago AI analysis › Press Release
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen management will attend the 24th Annual Morgan Stanley Global Healthcare Conference on September 15, 2026, for one-on-one investor meetings.
The company focuses on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
Its product portfolio includes Avance, Axoguard and Avive+ brands designed to restore nerve function and quality of life.
• 2mo ago AI analysis › Press Release ⚠ 3
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
Axogen reported Q2 2026 revenue of $69.7 million, up 23.1% year-over-year, surpassing the consensus of $68.4 million driven by over 50% growth in the breast reconstruction segment.
Despite raising full-year guidance to at least $279 million, the company's adjusted earnings of $0.12 per share missed consensus and gross margins dipped to 72.7%.
The commentary notes Axogen as a commercial-stage proof point for regenerative medicine in reconstructive surgery, though the article itself is a paid promotion for another entity.
• 2mo ago AI analysis › Press Release ⚠ 2
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
Axogen announced a strategic investment in Trace Biosciences to support the clinical development of Nerve Trace, a nerve-specific imaging technology. The investment is part of Trace's Series A financing round, though specific financial terms were not disclosed.
Trace's lead candidate, Nerve Trace Dx, received FDA IND clearance in December 2025 and is currently evaluating safety in a Phase I clinical trial. Proceeds from the financing are intended to support Phase II and III clinical trials toward a New Drug Application.
Axogen CEO Michael Dale stated the investment aligns with the company's mission to restore peripheral nerve function by giving surgeons the ability to visualize nerves in real time.
• 3mo ago AI analysis › Press Release ⚠ 3
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Axogen reported Q2 revenue of $69.7 million, up 23.1% year-over-year, driven by broad-based growth across Extremities, Oral Maxillofacial, and Breast segments.
Adjusted net income was $7.3 million, or $0.12 per share, flat compared to the prior year, while GAAP results reflected a net loss of $1.5 million.
The company reaffirmed 2026 guidance for at least 24% revenue growth, expecting full-year revenue of at least $279 million with positive free cash flow.
• 3mo ago AI analysis › Press Release ⚠ 1
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
Neuronetics announced the appointment of Nir Naor as its new Chief Financial Officer, effective July 23, 2026. Naor joins Neuronetics from Axogen (AXGN), where he most recently served as CFO and helped the company achieve profitability and cash flow positivity within one year.
Naor brings over 20 years of finance and life sciences experience to the role, having previously served as CFO of Arbor Pharmaceuticals and held leadership positions at Mölnlycke, UCB, and AstraZeneca. In connection with his new role, he received an inducement grant of 500,000 restricted stock units.
The announcement implies the departure of Naor from Axogen, where he is credited with contributing to a tripling of the company's market capitalization during his tenure.
• 3mo ago AI analysis › Press Release
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Axogen announced that it will report its second quarter 2026 financial results on Wednesday, July 29, 2026.
Management is scheduled to host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the quarterly performance.
The company focuses on developing and marketing surgical solutions for peripheral nerve repair.
• 3mo ago AI analysis › Press Release ● Major ⚠ 1
Axogen, Inc. Reports First Quarter 2026 Financial Results
Axogen delivered strong Q1 results with revenue rising 26.6% year-over-year to $61.5 million, driven by double-digit growth across all target markets. The company also shifted to profitability on an adjusted basis with net income of $4.1 million, or $0.07 per share.
Management maintained its full-year 2026 guidance, projecting revenue growth of at least 20% to $270 million and expecting to be free cash flow positive for the year. The balance sheet remains robust with $103.6 million in cash and investments following the repayment of the Oberland loan facility.
Business highlights included positive coverage decisions from major insurers Cigna and Elevance Health, alongside new CMS codes that increased facility reimbursement rates for the Avance nerve graft.
• 6mo ago AI analysis › 
